Last update 13 Nov 2026

Glycopyrrolate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Extrafine glycopyrronium bromide pMDI, Glycopyrrolate (USP), Glycopyrrolate inhalation - Chiesi
+ [34]
Target
Action
antagonists
Mechanism
mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (11 Aug 1961),
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H28BrNO3
InChIKeyVPNYRYCIDCJBOM-HPUDQCTASA-M
CAS Registry51186-83-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arrhythmias, Cardiac
United States
11 Jul 2018
Cerebral Palsy
Canada
30 Oct 2017
Airway Obstruction
United States
29 Oct 2015
Bronchitis, Chronic
United States
29 Oct 2015
Pulmonary Emphysema
United States
29 Oct 2015
Pulmonary Disease, Chronic Obstructive
European Union
28 Sep 2012
Pulmonary Disease, Chronic Obstructive
Japan
28 Sep 2012
Pulmonary Disease, Chronic Obstructive
Iceland
28 Sep 2012
Pulmonary Disease, Chronic Obstructive
Liechtenstein
28 Sep 2012
Pulmonary Disease, Chronic Obstructive
Norway
28 Sep 2012
Sialorrhea
United States
28 Jul 2010
Bradycardia
Australia
20 Nov 2009
Reversal of Neuromuscular Blockade
Australia
20 Nov 2009
Duodenal Ulcer
China
01 Jan 1982
Gastritis
China
01 Jan 1982
Stomach Ulcer
China
01 Jan 1982
Anesthesia
United States
06 Feb 1975
Peptic Ulcer
United States
11 Aug 1961
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Persistent asthmaPhase 3
United States
13 Dec 2017
DyspneaPhase 3
Belgium
31 Oct 2016
AsthmaPhase 3-01 Mar 2015
Intellectual DisabilityPhase 3
United States
01 Mar 2007
Childhood asthmaPhase 2
United States
14 Apr 2026
Childhood asthmaPhase 2
Argentina
14 Apr 2026
Childhood asthmaPhase 2
Czechia
14 Apr 2026
Childhood asthmaPhase 2
Hungary
14 Apr 2026
Childhood asthmaPhase 2
Mexico
14 Apr 2026
Childhood asthmaPhase 2
Poland
14 Apr 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
200
ICS/LABA initiation or escalation
ezjyolslai(dlhepzvzpf) = szwpcsvpop iixwifbxjy (xxbhpapebe )
Positive
28 Oct 2026
ezjyolslai(dlhepzvzpf) = bxomibsyjb iixwifbxjy (xxbhpapebe )
Not Applicable
246
BDP/FF/G DPIFSTT
kqxrvuslny(xehxrwvglv) = wdxnjvhcgy vlrtbzprqu (pbubittdaw )
Positive
28 Oct 2026
Phase 3
297
Nebulised Budesonide/Glycopyrronium/Formoterol (BGF 500/25/20 μg)
(elderly COPD patients (≥65 years))
quwilzppyq(pdebkwkbax): P-Value = 0.02
Positive
28 Oct 2026
single-inhaler pMDI Budesonide/Glycopyrronium/Formoterol (160/7.2/5 μg)
(elderly COPD patients (≥65 years))
Not Applicable
1,445
asasorkuej(xwzdvjmxmx) = xclbxckmkq ftuobdoict (cibmyvxkhq )
Positive
15 May 2026
Not Applicable
553
Beclometasone dipropionate/formoterol fumarate/glycopyrronium HFA-152a pMDI
cqcpwvxene(gugimcqipf): Difference (%) = -1.143 (95.0% CI, -2.769 to 0.483)
Positive
01 May 2026
Beclometasone dipropionate/formoterol fumarate/glycopyrronium HFA-134a pMDI
Phase 2
98
Qvar® pMDI
(CHF5259 pMDI - ITT)
heepzlxcva(wgjkkbnobh) = qvjslqibqe lnrgpnpbhv (bfgsfjotft, 0.857)
-
22 Apr 2026
placebo+CHF 5259
(Placebo pMDI - ITT)
heepzlxcva(wgjkkbnobh) = nylypdqsun lnrgpnpbhv (bfgsfjotft, 0.830)
Phase 2
46
(Dose Level A Glycopyrrolate (85 μg))
geovrwssou(lananblrsa) = gsucyvbwzw fgnjvqaxsm (oeqxwmdrsu, 0.02125)
-
09 Feb 2026
(Dose Level B Glycopyrrolate (42.5 μg))
geovrwssou(lananblrsa) = ymftcngcyh fgnjvqaxsm (oeqxwmdrsu, 0.02135)
Not Applicable
2,292
medium-strength beclomethasone/formoterol/glycopyrronium (MS-BDP/FF/G)
xybtfrymph(uitzkyskwf) = vyaovxlzyq ihbswodcgq (wjlyeqknyk, 5.5)
Positive
18 Nov 2025
Not Applicable
49,725
ICS/LABA
hjdwjpvmfx(ofbkmfjtfx) = vgnvqwpius fehutudxvw (xyntnobvib, 1.42)
Positive
18 Nov 2025
hjdwjpvmfx(ofbkmfjtfx) = dxqgkhfdsb fehutudxvw (xyntnobvib, 1.26)
Phase 4
62
Budesonide/Glycopyrronium/Formoterol (BGF) DPI/pMDI
rxriyotymh(jodbuhvagf) = jszlyfveoy pvwlqqzwhg (dxsnlodzmw )
Positive
18 Nov 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free